Close mobile menu×
Close mobile menu

Siddhartha Mukherjee, MD, DPhil

Board Certifications: 
Medical Oncology
Expertise in: 
Myelodysplastic Syndrome
Not Accepting New Patients
Profile Headshot

Appointments

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Medical Oncology

Clinical Expertise

  • Myelodysplastic Syndrome
  • Myeloma
  • Lymphoma

Specialties

Education & Training

  • 2000 Harvard Medical School
  • Residency: 2003 Massachusetts General Hospital
  • Fellowship: 2006 Dana Farber Cancer Institute - Harvard Medical School

About Siddhartha Mukherjee

Hematologist and oncologist Siddhartha Mukherjee was born in New Delhi, India. He holds a BS in biology from Stanford University, a DPhil in immunology from Oxford University (where he was a Rhodes Scholar), and an MD from Harvard Medical School. He completed his internal medicine residency and an oncology fellowship at Massachusetts General Hospital. Dr. Murkherjee is an assistant professor of medicine at Columbia University Medical Center. He lives in Manhattan with his wife, artist Sarah Sze, and their two daughters.

His Pulitzer Prize-winning book, The Emperor of All Maladies: A Biography of Cancer, tells the story of cancer from its first description in an ancient Egyptian scroll to the gleaming laboratories of modern research institutions. A three-part documentary series based on the book, directed by Barak Goodman and executive produced by Ken Burns, debuts on PBS stations March 30 and continues on March 31 and April 1. The film interweaves a sweeping historical narrative with intimate stories about contemporary patients and an investigation into the latest scientific breakthroughs.

Academic Titles

  • Assistant Professor of Medicine

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Amida Care

  • Special Needs Plan

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield

  • NYP Employee Plan

MagnaCare

  • MagnaCare

UnitedHealthcare

  • Columbia University Employee Plan

VNSNY CHOICE

  • Medicare Managed Care

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Research

Dr. Mukherjee’s research lab studies the biology of blood development, in particular, malignant and pre-malignant diseases such as myelodysplasia (MDS) and acute myelogenous leukemia (AML). The eventual goal is to develop novel drugs against these diseases.

Grants

TARGETING SPLICING FACTOR MUTATIONS IN MYELDYSPLASTIC SYNDROMES IN CANCER (Private)

Jun 1 2018 - May 31 2021

OSTEOCHONDRORETICULAR (OCR) CELLS AS SOURCES OF CARTILAGE REPAIR IN OSTEOARTHRITIS (Federal Gov)

Jul 1 2016 - Jun 30 2020

A PHASE 1 TRIAL OF PERSONALIZED/PRECISION THERAPEUTICS FOR MYELODYSPLASTIC SYNDROME (MDS) USING BONE MARROW ORGANOID (BM-O) SCREENING (Private)

Apr 1 2016 - Mar 31 2019

PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITION TO TREAT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) (Private)

Feb 26 2016 - Feb 25 2019

YES 1 AND CTNND1 AS QUIESCENCE REGULATORS IN HEMATOPOIETIC STEM CELLS (Federal Gov)

Aug 1 2013 - Apr 30 2018

CLINICAL ANNOTATION AND PERSONALIZED TREATMENT FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES (Private)

Nov 1 2014 - Oct 31 2016

CENTER FOR HIGH-THROUGHPUT MINIMALLY-INVASIVE RADIATION BIODOSIMETRY (Federal Gov)

Aug 31 2005 - Jul 31 2016

THE ROLE OF XLF IN HEMATOPOIETIC STEM CELL MAINTENANCE AND FUNCTION (Federal Gov)

Aug 15 2013 - Jul 31 2015

ILLUMINATE THE PATHOPHYSIOLOGY OF MDS WITH SRSF2 (Private)

Jul 1 2014 - Jun 30 2015

EXOME AND NEXT GENERATION SEQUENCING TO IDENTIFY RARS-SPECIFIC TARGETABLE DEFECTS (Private)

Jul 1 2012 - Jun 30 2014

COLLABORATIVE EFFORT IN STEM CELL BIOLOGY (Private)

Jul 1 2010 - Jun 30 2014

CANCER STEM CELL SPECIFIC LETHALITY IN ACUTE MYELOID LEUKEMIA STEM CELLS BY MODULATION OF PES-1 AND DFFB (Private)

Jan 1 2012 - Dec 31 2013

DISSECTING THE ROLES OF YES-1, MIIT3 AND CTNND1 IN LEUKEMIA STEM CELL QUIESCENCE (Private)

Jan 1 2011 - Dec 31 2013

IDENTIFICATION OF FUNCTIONAL TUMOR-STROMAL INTERACTIONS IN T HE BONE MARROW (Federal Gov)

Sep 30 2009 - Aug 31 2012

THE REGULATION OF LEUKEMIA-ENGRAFTING CELLS BY THE HEMATOPOE ITIC STEM CELL NICHE (Federal Gov)

Sep 30 2006 - Jul 31 2011